[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"coronary-microvascular-dysfunction-cmd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:coronary-microvascular-dysfunction-cmd":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,50,84,112,134,175,201,221,244,274,304,333,361,382,408],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":4},"100637367","phase-2-effect-of-guanxinning-tablet-on-coronary-microcirculation-after-primary-percutaneous-coronary-intervention-in-patients-with-acute-myocardial-infarction-100637367",false,"NCT07621107","Effect of Guanxinning Tablet on Coronary Microcirculation After Primary Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction","A Randomized Explorative Pre-trial of the Effect of Guanxinning Tablet on Coronary Microcirculation After Primary Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction","Inclusion Criteria:\n\n* Age between 18 and 80 years (gender is not restricted).\n* STEMI diagnosed for the first time and with an onset time within 12 hours. (According to the \"Chinese Guidelines for the Diagnosis and Treatment of Acute ST - Segment Elevation Myocardial Infarction 2019\" and the fourth - edition \"Global Definition of Myocardial Infarction\" criteria, myocardial infarction refers to acute myocardial injury \\[serum cardiac troponin (cTn) increases and\u002For decreases, and at least once is higher than the upper limit of the normal value (the 99th percentile of the upper limit of the reference value)\\], along with clinical evidence of acute myocardial ischemia, including: (1) Symptoms of acute myocardial ischemia; (2) New ischemic electrocardiogram changes; (3) New pathological Q - wave; (4) New imaging evidence of viable myocardial loss or abnormal wall segmental motion; (5) Coronary artery thrombosis confirmed by coronary angiography, intracavitary imaging examination, or autopsy.)\n* Successfully received PPCI treatment (assessed by visual inspection or quantitative coronary angiography, with residual stenosis of the target lesion \\\u003C 20% after stent implantation or \\\u003C 50% after simple balloon dilation, and forward TIMI blood flow ≥ grade 2).\n* Signed a written informed consent form.\n\nExclusion Criteria:\n\n* Cardiogenic shock with poor response to vasoactive drugs; or uncontrolled acute left - heart failure or pulmonary edema; uncontrolled malignant arrhythmia.\n* LVEF \\\u003C 40%.\n* Currently using nicorandil, other Chinese patent medicines, and Chinese herbal decoctions, etc.\n* Unable to undergo CMR examination for various reasons.\n* Expected to be unable to complete 6 - month treatment with Guanxinning Tablets.\n* Contraindications or allergies to Guanxinning Tablets.\n* Suspected or confirmed hereditary cardiomyopathy (such as hypertrophic, dilated, obstructive cardiomyopathy, cardiac amyloidosis, hemochromatosis cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, etc.).\n* Active or chronic liver disease.\n* Renal insufficiency (eGFR \\\u003C 60ml\u002Fmin\u002F1.73m²).\n* History of previous cerebral hemorrhage.\n* History of alcohol or drug abuse.\n* Known active infection, or severe hematological, metabolic, or endocrine dysfunction.\n* Patients who have received systemic steroid or cyclosporine treatment in the past 3 months.\n* Active malignant tumor.\n* Life expectancy less than 6 months.\n* Pregnant or lactating women.\n* Already participating in other clinical studies.","ALL","18 Years","80 Years",{"count":20,"type":21},70,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","①Research objective: In a small sample population, through the pre - experimental method, explore and evaluate the effect of Guanxinning tablets on the coronary microcirculation after primary percutaneous coronary intervention (PPCI) in patients with acute ST - segment elevation myocardial infarction (STEMI), with the change in the percentage of intramyocardial hemorrhage (IMH) in ventricular mass measured by cardiac magnetic resonance (CMR) imaging as the primary endpoint.\n\n②Research significance: The research results of this project will provide preliminary theoretical basis and methodological support for the formal randomized controlled study on evaluating the effect of Guanxinning tablets on the coronary microcirculation after PPCI in STEMI patients. It will offer new ideas for the long - term clinical treatment of STEMI patients after PPCI, and provide important theoretical support for expanding the clinical indications of Guanxinning tablets and exploring the reasons for its improvement of cardiovascular outcomes.",[27,28,29,30,31],"STEMI (ST Elevation MI)","STEMI - ST Elevation Myocardial Infarction","STEMI","CMD","Coronary Microvascular Dysfunction (CMD)",[33,34,35,36,37],"TCM","traditional chinese medicine","guanxinning tablet","CMR","intramyocardial hemorrhage","NOT_YET_RECRUITING","2026-05-27",{"date":41,"type":42},"2026-06-02","ACTUAL",{"date":44,"type":21},"2026-06-01",{"date":46,"type":21},"2027-02-01",{"name":48,"class":49},"Beijing Anzhen Hospital","OTHER",{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":22,"phases":63,"briefSummary":65,"conditions":66,"keywords":69,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":79,"leadSponsor":81,"locationsCount":83},"100639304","invasive-evaluation-and-phenotype-guided-treatment-of-anoca-in-women-100639304","NCT07593157","Invasive Evaluation and Phenotype-Guided Treatment of ANOCA in Women","Invasive Functional and Morphological Coronary Assessment Followed by Phenotype-Guided Multidisciplinary Treatment in Women With Angina and Non-Obstructive Coronary Arteries: A Prospective Single-Center Interventional Study","ANOCA-UY","Inclusion Criteria:\n\n* Female participants aged 35 to 75 years.\n* Symptoms compatible with stable angina or suspected myocardial ischemia.\n* Non-obstructive coronary arteries, defined as absence of angiographic stenosis greater than or equal to 50%.\n* Ability to undergo invasive coronary assessment and clinical follow-up.\n* Written informed consent.\n\nExclusion Criteria:\n\n* Significant structural heart disease.\n* Severe left ventricular systolic dysfunction, defined as left ventricular ejection fraction \\\u003C40%.\n* Clinically relevant contraindication to adenosine or acetylcholine, including severe asthma, untreated high-grade atrioventricular block, or known hypersensitivity.\n* Active oncological disease or life expectancy less than 12 months.\n* Inability to complete the diagnostic or therapeutic study protocol.\n* Participation in another clinical study that could interfere with the present protocol.","FEMALE","35 Years","75 Years",{"count":62,"type":21},50,[64],"NA","This prospective single-center interventional study will include women with angina and non-obstructive coronary arteries. Participants will undergo a standardized invasive coronary assessment combining coronary physiology, acetylcholine provocation testing, and optical coherence tomography. The diagnostic protocol will identify functional and morphological mechanisms of angina, including microvascular dysfunction, epicardial vasospasm, microvascular spasm, endothelial dysfunction, functional epicardial disease, combined mechanisms, or normal coronary physiology.\n\nBased on the identified phenotype, participants will receive individualized multidisciplinary treatment, including targeted pharmacological therapy, adapted cardiovascular rehabilitation, and psycho-emotional support when indicated. Clinical follow-up will be performed at 1, 6, and 12 months to assess angina symptoms, quality of life, functional capacity, adherence to treatment, and cardiovascular events.",[67,31,68],"ANOCA - Angina With Non-obstructive Coronary Arteries","Vasospastic Angina",[70,71,72,73,74],"Angina with non-obstructive coronary arteries","ANOCA","INOCA","Vasospastic angina","Coronary Microvascular Dysfunction","2026-05-15",{"date":77,"type":42},"2026-05-18",{"date":75,"type":21},{"date":80,"type":21},"2029-04-30",{"name":82,"class":49},"Hospital de Clínicas Dr. Manuel Quintela",1,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":22,"phases":93,"briefSummary":94,"conditions":95,"keywords":100,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":108,"leadSponsor":110,"locationsCount":4},"100627470","comprehensive-invasive-physiological-evaluation-of-obstructive-coronary-artery-disease-100627470","NCT07449052","Comprehensive Invasive Physiological Evaluation of Obstructive Coronary Artery Disease","Inclusive Invasive Physiological Assessment in Angina Syndromes - Obstructive Coronary Artery Disease","Inclusion Criteria:\n\n* Patients \\>18 years of age\n* Hemodynamically relevant obstructive coronary artery disease (as assessed by pressure wire evaluation) in the left anterior descending coronary artery amenable to percutaneous coronary intervention at the discretion of the operator.\n\nExclusion Criteria:\n\n* Prior coronary artery bypass graft surgery.\n* Stenosis \\>90% in the target vessel or a stenosis deemed unsafe for pressure wire instrumentation\n* Known severe left ventricular dysfunction (left ventricular ejection fraction by any imaging modality)\n* Severe valvular disease\n* Renal impairment (estimated glomerular filtration rate \\\u003C30mL\u002Fmin)\n* Contra-indications for the use of adenosine or acetylcholine\n* Expected inability to conform to the clinical follow-up\n* Unable or unwilling to use the ORBITA-app\n* Life expectancy of less than 12 months.",{"count":92,"type":21},450,[64],"The goal of this clinical trial is to test whether adding coronary function testing and starting targeted medical treatment for identified vasomotor disorders will also improve angina symptoms and quality of life in patients with obstructive coronary artery disease who undergo percutaneous coronary intervention. The main question it aims to answer is:\n\nDoes performing coronary function testing in patients with obstructive coronary artery disease who undergo percutaneous coronary intervention lead to better relieve of angina symptoms and improvement in quality of life?\n\nResearchers will compare this group undergoing coronary function testing with a control group who will solely undergo percutaneous coronary intervention.\n\nParticipants will:\n\n* Undergo percutaneous coronary intervention and coronary function testing in the intervention arm\n* Undergo percutaneous coronary intervention in the control arm",[96,97,31,98,99],"Coronary Artery Disease (CAD)","Obstructive Coronary Artery Disease","Vasospasm, Coronary","Stable Angina Pectoris",[101,102,103],"Coronary Function Testing","Percutaneous Coronary Intervention","Stable Angina","2026-04-30",{"date":106,"type":42},"2026-05-01",{"date":106,"type":21},{"date":109,"type":21},"2029-03-01",{"name":111,"class":49},"UMC Utrecht",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":22,"phases":121,"briefSummary":123,"conditions":124,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":4},"100633981","phase-3-precise-phenotyping-to-guide-therapies-for-coronary-microvascular-dysfunction-100633981","NCT07533747","PRECISE Phenotyping to Guide Therapies for Coronary Microvascular Dysfunction","PRECISE-CMD","Inclusion Criteria:\n\n* Angina with non-obstructive coronary arteries\n\nExclusion Criteria:\n\n* Significant epicardial coronary stenoses\n* Inability to carry out bike exercise\n* Contra-indication to adenosine administration\n* Insulin usage with frequent hypoglycaemic episodes",{"count":120,"type":21},100,[122],"PHASE3","Some people experience chest pain and shortness of breath, but when they have tests, no blockages are found in their main heart arteries. The most common cause of symptoms is related to abnormalities in the small blood vessels, also known as 'small vessel angina' or Coronary Microvascular Dysfunction (CMD). Currently, the diagnosis of CMD requires additional measurements of blood flow in the heart vessel during a minimally invasive procedure known as a coronary angiogram.\n\nCMD affects many people and can lead to repeated hospital visits and a lower quality of life, and diagnosing the condition leads to better patient outcomes. However, there are still no widely available, proven treatments for this condition and therefore several patients remain symptomatic.\n\nThis study aims to find better ways to treat CMD, especially by understanding how the heart uses energy and how this might relate to symptoms.",[31],"2026-04-10",{"date":127,"type":42},"2026-04-16",{"date":129,"type":21},"2026-05",{"date":131,"type":21},"2031-05",{"name":133,"class":49},"King's College London",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":22,"phases":144,"briefSummary":145,"conditions":146,"keywords":155,"overallStatus":164,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":174},"100414271","icormica---stratified-medicine-in-angina-100414271","NCT04674449","iCorMicA - Stratified Medicine in Angina","International Study of Coronary Microvascular Angina (iCorMicA): a Randomised, Controlled, Multicentre Trial and Registry","iCorMicA","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. A clinical plan for invasive coronary angiography.\n3. Symptoms of angina (typical or atypical) according to the Rose- and\u002For Seattle Angina questionnaires.\n4. Able to comply with study procedures.\n5. Able to provide informed consent.\n\nExclusion Criteria:\n\n1. A non-coronary primary indication for invasive angiography (e.g. valve disease, heart failure).\n2. History of coronary artery bypass surgery.\n3. Presence of obstructive disease evident in a main coronary artery (diameter \\>2.5 mm), i.e. a coronary stenosis \\>50% and\u002For a fractional flow reserve (FFR) ≤0.80\\*.\n4. Logistical reason\\*. \\*These patients will enter a follow-up registry.",{"count":143,"type":21},1500,[64],"The iCorMicA study is a multicentre, prospective, randomised, double-blind, sham-controlled, parallel-group, end-point trial and registry. The investigators seek to determine whether stratified medical therapy guided by an adjunctive interventional diagnostic procedure (IDP) during the invasive management of patients with known or suspected angina but no obstructive coronary artery disease improves symptoms, wellbeing, cardiovascular risk and clinical outcomes.",[147,148,149,31,150,151,152,68,153,154],"Microvascular Angina","Angina, Stable","Ischemia With No Obstructive Coronary Arteries (INOCA)","Ischaemic Heart Disease","Non-Obstructive Coronary Atherosclerosis","Coronary Artery Disease","Coronary; Ischemic","Angina Attacks",[156,157,158,159,160,161,162,163],"angina","microvascular angina","ischaemia with no obstructive coronary artery disease (INOCA)","stratified medicine","clinical trial","outcomes research","prognosis","health economics","RECRUITING","2026-04-03",{"date":167,"type":42},"2026-04-09",{"date":169,"type":42},"2020-12-30",{"date":171,"type":21},"2030-12-31",{"name":173,"class":49},"NHS Greater Glasgow and Clyde",39,{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":181,"targetDuration":4,"studyType":183,"phases":4,"briefSummary":184,"conditions":185,"keywords":186,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":200},"100627803","multisensor-wireless-pressure-microcatheter-for-microvascular-function-assessment-in-anocainoca-patients-a-prospective-multicenter-single-group-target-value-study-100627803","NCT07453381","Multisensor Wireless Pressure Microcatheter For Microvascular Function Assessment In ANOCA\u002FINOCA Patients: A Prospective, Multicenter, Single-Group Target Value Study","Inclusion Criteria:\n\n1. Age ≥ 18 years, gender not limited;\n2. Symptoms of angina pectoris, or objective evidence of myocardial ischemia (e.g., electrocardiogram, myocardial injury markers, etc.);\n3. Visual assessment of coronary angiography shows diameter stenosis \\\u003C 50% and FFR \\> 0.8 (or cRR \\> 0.89);\n4. Microvascular function assessment is planned;\n5. Agree to participate in this clinical study and voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n1. Acute myocardial infarction, PCI, CABG, or valvular surgery following angiography within the past 30 days;\n2. Severe valvular disease requiring surgical or interventional treatment;\n3. Chest pain with known non-ischemic causes (e.g., pericarditis, pulmonary hypertension, esophageal spasm);\n4. Contraindications to CMR (e.g., certain types of pacemakers or defibrillators, severe claustrophobia);\n5. Clear contraindications to adenosine and ATP use (e.g., second- or third-degree atrioventricular block, sick sinus syndrome, severe asthma, systolic blood pressure below 90 mmHg);\n6. Renal insufficiency (eGFR ≤ 45 mL\u002Fmin\u002F1.73 m2) or currently undergoing dialysis;\n7. Severe heart failure or LVEF ≤ 35%;\n8. Severe organ disease or life expectancy less than 2 years;\n9. Known to be participating in other drug or device clinical trials that have not yet met the primary endpoint;\n10. Other investigators deem the candidate unsuitable for this clinical trial.",{"count":182,"type":21},114,"OBSERVATIONAL","This study aims to evaluate the sensitivity and specificity of a multi-sensor wireless pressure microcatheter for the diagnosis of CMD in patients with ANOCA\u002FINOCA, using quantitative myocardial perfusion imaging of cardiac magnetic resonance (CMR) as a reference.",[31],[187,188,189,190,74],"Pressure Microcatheter","Microvascular Function Assessment","Angina with Non-obstructive Coronary Arteries","Ischaemia with Non-obstructive Coronary Arteries","2026-03-01",{"date":193,"type":42},"2026-03-06",{"date":195,"type":21},"2026-03-23",{"date":197,"type":21},"2026-10-31",{"name":199,"class":49},"Peking University Third Hospital",3,{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":205,"acronym":206,"eligibilityCriteria":207,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":208,"targetDuration":4,"studyType":22,"phases":209,"briefSummary":210,"conditions":211,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":4},"100618852","comprehensive-diagnostic-assessment-of-coronary-endothelial-function-impairment-and-vasospasm-with-continuous-thermodilution-in-patients-with-suspected-coronary-microvascular-and-vasomotor-dysfunction-100618852","NCT07337005","CompREhensive Diagnostic Assessment of Coronary Endothelial Function Impairment and Vasospasm With CoNtinuous ThErmodilution in Patients With Suspected Coronary Microvascular and Vasomotor Dysfunction","REDEFINE-CMD","Inclusion Criteria:\n\n1. Patients with symptoms suggestive of angina.\n2. Evidence of unobstructed coronary arteries on invasive or non-invasive coronary angiography (coronary stenosis \\\u003C50% and \u002For FFR \\>0.80).\n3. Above the age of 18.\n4. The subject has been informed of the nature of the study, agrees to its provisions and has signed written informed consent.\n\nExclusion Criteria:\n\n1. Pregnancy.\n2. Contraindication to angiography and\u002For physiological assessment with adenosine or acetylcholine.\n3. Previous coronary artery bypass graft (CABG).\n4. Moderate to severe valvular heart disease.",{"count":120,"type":21},[64],"The goal of this observational study is to learn more about the diagnosis of coronary endothelium function and coronary vasospasm using a dedicated invasive protocol in patients who has angina without obstruction in their main heart arteries. The main question it aims to answer is the feasibility, reproducibility, and safety of this invasive protocol:\n\nDoes this invasive protocol diagnose coronary endothelial dysfunction and vasospasm without issues?\n\nParticipants already having invasive coronary angiogram and physiological studies will undergo additional physiological measurements during the same procedure.\n\nParticipants will enrol in a symptoms and quality of life questionnaire using dedicated questionnaires and a mobile application to assess the burden of their symptoms before and after the invasive procedure and up to 12 months follow up.\n\nA subset of participants will undergo a repeat set of these measurements to assess reproducibility of the invasive protocol.\n\nA subset of the participants will also undergo a cardiac MRI to assess correlation with the invasive protocol measurements.",[31,98],"2026-01-07",{"date":214,"type":42},"2026-01-13",{"date":216,"type":21},"2025-12-15",{"date":218,"type":21},"2027-12",{"name":220,"class":49},"Mid and South Essex NHS Foundation Trust",{"id":222,"slug":223,"hasResults":11,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":227,"eligibilityCriteria":228,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":229,"targetDuration":231,"studyType":183,"phases":4,"briefSummary":232,"conditions":233,"keywords":235,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":83},"100617190","the-correlation-between-obstructive-sleep-apnea-related-nocturnal-hypoxemia-parameters-and-coronary-microvascular-dysfunction-a-prospective-cohort-study-sleep-cmd-100617190","NCT07315399","The Correlation Between Obstructive Sleep Apnea-Related Nocturnal Hypoxemia Parameters and Coronary Microvascular Dysfunction: A Prospective Cohort Study (SLEEP-CMD)","The Correlation Between Obstructive Sleep Apnea-Related Nocturnal Hypoxemia Parameters and Coronary Microvascular Dysfunction: A Prospective Cohort Study","SLEEP-CMD","Inclusion Criteria:\n\n1. Aged 18 to 80 years, of any gender.\n2. Scheduled for elective coronary angiography due to symptoms or evidence of myocardial ischemia.\n3. Agreed to and capable of completing overnight polysomnography (PSG) monitoring.\n4. Provided written informed consent and were willing and able to comply with baseline assessments and long-term follow-up.\n\nExclusion Criteria:\n\n1. Presence of coronary chronic total occlusion (CTO), history of coronary artery bypass grafting (CABG), severe valvular heart disease, dilated or hypertrophic cardiomyopathy, congenital heart disease, or heart failure (NYHA functional class III-IV).\n2. Sleep-disordered breathing with central sleep apnea (CSA) as the primary manifestation.\n3. Severe hepatic insufficiency (Child-Pugh class C) or renal failure (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²).\n4. Pregnancy or lactation.\n5. Life expectancy of less than 2 years, or any other condition that the investigators considered unsuitable for participation in the study.",{"count":230,"type":21},560,"36 Months","In a cohort of patients with suspected myocardial ischemia undergoing sleep studies, the objectives of this study were:\n\n1. To determine the association between various obstructive sleep apnea (OSA)-related nocturnal hypoxemia parameters and coronary microvascular dysfunction (CMD) in patients with suspected myocardial ischemia.\n2. To compare the predictive value of nocturnal hypoxemia parameters versus the traditional Apnea-Hypopnea Index (AHI) for coronary microvascular dysfunction.\n3. To evaluate the prognostic value of nocturnal hypoxemia parameters in predicting Major Adverse Cardiovascular Events (MACE) during the follow-up period.\n4. To explore the potential mediating roles of inflammatory and oxidative stress biomarkers in the relationship between nocturnal hypoxemia parameters and coronary microvascular dysfunction.",[234,31,96],"OSA - Obstructive Sleep Apnea",[234,74,152],"2025-12-18",{"date":238,"type":42},"2026-01-02",{"date":240,"type":21},"2025-12-30",{"date":242,"type":21},"2030-12-30",{"name":48,"class":49},{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":248,"acronym":249,"eligibilityCriteria":250,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":251,"targetDuration":4,"studyType":183,"phases":4,"briefSummary":253,"conditions":254,"keywords":258,"overallStatus":164,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":266,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":272,"locationsCount":83},"100610061","the-impact-of-renal-transplant-on-coronary-microvascular-function-among-patients-with-advanced-chronic-kidney-disease-100610061","NCT07222683","The Impact of Renal Transplant on Coronary Microvascular Function Among Patients With Advanced Chronic Kidney Disease","RESTORE","Inclusion Criteria:\n\n* Renal transplant candidate on the waitlist\n* Age greater or equal to 45 years, or if 18-44 years of age on dialysis for 5 years or more\n\nExclusion Criteria:\n\n* Left ventricular ejection fraction (LVEF) \\\u003C 40%\n* History of coronary artery bypass grafting (CABG)\n* History of heart transplant\n* Patients who undergo revascularization as a result of pre-transplant cardiac PET",{"count":252,"type":21},80,"People with chronic kidney disease (CKD) often experience faster aging of the heart and blood vessels, which raises the risk of heart problems beyond traditional factors like high blood pressure or cholesterol. One early sign is reduced blood flow in the tiny vessels that supply the heart, measured by a positron emission tomography (PET) scan using a marker called myocardial flow reserve (MFR). In CKD, ongoing inflammation and abnormal blood vessel growth can damage these small vessels, leading to heart stiffness and weaker heart function.\n\nA kidney transplant offers a unique chance to study how better kidney function and reduced inflammation affect heart health. The observational RESTORE study (\"Impact of Renal Transplant on Coronary Microvascular Function in Patients with Advanced CKD\") will measure heart blood flow and function before and after transplant.\n\nThe study will test whether:\n\n1. Inflammation and abnormal vessel growth are linked to poor heart blood flow and heart function in CKD.\n2. Kidney transplant improves heart blood flow and function.\n3. Lower inflammation after transplant leads to better heart health.\n\nBy understanding how kidney disease and inflammation affect the heart-and how transplant may reverse these effects-this research could help guide future treatments to better protect heart health in patients with CKD.",[255,256,31,257],"Chronic Kidney Disease","Kidney Transplant","Inflammation",[259,260,261,262,263,264],"chronic kidney disease","coronary microvascular dysfunction","kidney transplant","cardiovascular inflammation","dysregulated angiogenesis","coronary artery disease","2025-10-28",{"date":267,"type":42},"2025-10-30",{"date":269,"type":42},"2023-03-10",{"date":271,"type":21},"2030-07",{"name":273,"class":49},"Brigham and Women's Hospital",{"id":275,"slug":276,"hasResults":11,"nctId":277,"briefTitle":278,"officialTitle":279,"acronym":280,"eligibilityCriteria":281,"healthyVolunteers":11,"sex":58,"minAge":17,"maxAge":4,"enrollmentInfo":282,"targetDuration":4,"studyType":22,"phases":284,"briefSummary":286,"conditions":287,"keywords":290,"overallStatus":164,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":302,"locationsCount":83},"100562208","phase-1-study-targeting-myocardial-perfusion-and-symptom-relief-in-women-with-sglt2-inhibitors-strong-100562208","NCT06600178","Study Targeting Myocardial Perfusion and Symptom Relief in Women With SGLT2 Inhibitors (STRONG)","Innovative Therapy to Treat Women With Angina With Nonobstructive Coronary Artery Disease (ANOCA) and Coronary Microvascular Disease","STRONG","Inclusion Criteria:\n\n* • Female sex.\n\n  * Age ≥18 years.\n  * Willing and able to provide written informed consent.\n  * Signs and symptoms of suspected ischemia prompted referral for further evaluation by cardiac catheterization or CCTA within two years of consent.\n  * No evidence of obstructive epicardial CAD (stenosis \\\u003C50%) of a major epicardial vessel or an FFR ≤0.80 by invasive catheterization or CCTA. Patients who have not undergone cardiac catheterization of CT angiogram within the last 2 years for chest pain can be scheduled for a screening CT angiogram of the coronary arteries to confirm eligibility.\n  * Diagnosis of CMD defined by CFR \\< 2 by CMR\n  * Never on SGLT2i\n\nExclusion Criteria:\n\n* History of non-ischemic cardiomyopathy LVEF \\\u003C40% or hypertrophic cardiomyopathy.\n* History of congestive heart failure, severe pulmonary disease, liver disease\n* History of acute coronary syndrome (ACS) within previous 30 days\n* Stroke within the last 180 days or intracranial hemorrhage at any time.\n* Severe valvular disease\n* Life expectancy \\\u003C3 years, due to non-cardiovascular comorbidity.\n* Pregnancy or women who are breast-feeding\n* Type 1 diabetes mellitus\n* Symptomatic hypotension or systolic BP \\>95 mmHg on 2 consecutive measurements\n* Active malignancy requiring treatment at the time of visit\n* Severe (eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m2 by CKD-EPI), unstable, or rapidly progressing renal disease at the time of randomization\n* History of recurrent UTI\u002Fbladder\u002Fkidney infections\n* Asthma with ongoing wheezing\n* Known or suspected broncho-constrictive or bronchospastic lung disease (ARDS, emphysema)\n* Greater than first degree heart block\n* Implanted cardiac device\n* Profound sinus bradycardia (heart rate \\\u003C40 beats per minute)\n* Atrial fibrillation or supraventricular arrhythmias at time of imaging\n* Known intolerance of nitrates (other than hypotension)\n* History of reaction to iodinated contrast agents",{"count":283,"type":21},150,[285],"PHASE1","The goal of this clinical trial is to that Sodium-glucose cotransporter 2 inhibitors treatment will improve Coronary Microvascular Disease with anginal symptoms associated with non-obstructive coronary disease in women. The main questions it aims to answer are:\n\nAim 1: Test the hypothesis that Sodium-glucose cotransporter 2 inhibitors treatment improves coronary microvascular disease in women with no evidence of epicardial obstructive coronary artery disease.\n\nAim 2: Test the hypothesis that Sodium-glucose cotransporter 2 inhibitors treatment improves angina symptoms and other quality of life measurements associated with the improvement of CFR.\n\nAIM 3: Identify the effect of Sodium-glucose cotransporter 2 inhibition on inflammation pathways and markers of systemic Research will compare Brezavvy to placebo\n\nParticipants will:\n\n* Take study drug or placebo for 12 weeks\n* Stress Cardiac magnetic resonance imaging\n* 12 lead electrocardiograms\n* Complete questionnaires",[288,289,31],"Angina Patients With Non-obstructive Coronary Artery Disease","Coronary Microvascular Disease",[291,71,292,30,293,294],"Angina","Non-obstructive Coronary Artery Disease","Non-Obstructive CAD","Chest Pain in Women","2025-10-27",{"date":297,"type":42},"2025-10-29",{"date":299,"type":42},"2025-06-27",{"date":301,"type":21},"2026-10",{"name":303,"class":49},"University of Virginia",{"id":305,"slug":306,"hasResults":11,"nctId":307,"briefTitle":308,"officialTitle":308,"acronym":309,"eligibilityCriteria":310,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":311,"targetDuration":4,"studyType":22,"phases":313,"briefSummary":314,"conditions":315,"keywords":317,"overallStatus":164,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":324,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":330,"locationsCount":332},"100568489","microvascular-coronary-rehabilitation-for-improving-treatment---feasibility-study-100568489","NCT06681896","Microvascular Coronary Rehabilitation For Improving Treatment - Feasibility Study","MICROFIT","Inclusion Criteria:\n\n* Age ≥18\n* Angina or angina equivalent symptoms\n* Unobstructed coronary arteries at the time of coronary angiogram. This will be defined as plaque causing \\\u003C40% epicardial vessel stenosis or 40-90% with a fractional flow reserve (FFR) ≥0.8\n* Evidence of microvascular dysfunction on ICA (CFR \\\u003C2.5 and\u002For AchFR \\\u003C1.5)\n\nExclusion Criteria:\n\n* New York Heart Association class III\u002FIV heart failure\n* Severe left ventricular impairment (ejection fraction≤35%)\n* Severe heart valve disease\n* Significant cardiomyopathy (as assessed by a cardiologist)\n* Severe hypertension (defined as blood pressure \\>180\u002F120mmHg (despite three anti-hypertensive agents)\n* Uncontrolled arrhythmia\n* A history of aortic dissection, recent (\\\u003C6 months) acute pulmonary embolus, deep vein thrombosis, stroke or transient ischaemic attack, severe autonomic or peripheral neuropathy, acute systemic illness or fever, severe acute or chronic renal failure, severe pulmonary fibrosis or interstitial lung disease (in line with other trials investigating HIIT exercise)\n* Pregnancy or breastfeeding (at any point during the study. Patients becoming pregnant during the study will be asked to withdraw due to additional radiation exposure and risks from HIIT)\n* Physical inability to participate in exercise\n* Significant claustrophobia or metallic implants which would limit MRI imaging\n* Intolerance to regadenoson testing (high degree atrioventricular block, severe asthma or airways disease)\n* Current participation in another intervention-based trial\n* Inability to fully understand the verbal and written descriptions of the study and instructions provided during the study duration.",{"count":312,"type":21},40,[64],"The goal of this clinical trial is to assess the feasibility of undertaking a randomized controlled trial assessing the impact of a personalised, intense cardiac rehabilitation programme involving high intensity interval exercise (HIIT) and dietary advice (termed MICROFIT) on symptom burden in patients with microvascular coronary dysfunction.\n\nThe main questions it aims to answer are:\n\n1. Feasibility of undertaking randomised controlled trial of MICROFIT in patients with coronary microvascular dysfunction (recruitment rates, retention and adherence, acceptability of MICROFIT and participants' and practitioners' experiences of trial participation)\n2. Preliminary data on the effect that MICROFIT has on angina symptoms in patients with microvascular coronary dysfunction, as measured by Seattle Angina Questionnaire\n3. Preliminary data on the fidelity and clinical efficacy of MICROFIT\n\nParticipants will be randomized to either MICROFIT + Usual Care, or Usual Care group.\n\nParticipants in both arms of the trial will:\n\n* Undergo a series of investigations, including cardiopulmonary exercise test (CPET), dual xray absorptiometry (DEXA), echocardiogram, cardiac MRI scan, blood tests, at the start of the trial and again after 6 months\n* Measure their living activity by using an activity tracker (GeneActiv) as well as a photographic diet diary for a week at the start of the trial and again after 6 months\n* Complete a series of questionnaires to assess angina symptom burden, mental health and quality of life, at the start of the trial and again after 6 months.\n\nParticipants in the intervention arm of the study will:\n\n1. Undergo MICROFIT intervention. MICROFIT includes a combination of exercise and diet management sessions over 24 weeks. It involves:\n\n   * 1:1 high-intensity interval training ('HIIT') sessions with a personal trainer and guidance on exercise sessions to be performed at home\n   * 1:1 sessions with a dietician to support them with improvements in diet.\n2. Visit clinic on two additional occassions during the trial to discuss their progress with a cardiologist\n3. Undergo an interview at the end of the study to discuss their experiences of participation in the study\n4. Receive a debrief on their investigation results and progress made at the end of their study\n\nParticipants in the Usual Care arm of the study will:\n\n1. Receive standard Usual Care advice regarding lifestyle changes and targeted medical therapy offered to patients with coronary microvascular dysfunction.\n2. Receive a debrief on their investigation results and progress made at the end of their study\n3. Undergo a 'taster' session with the personal trainer to discover what the intervention involves.",[316,147,31],"Microvascular Coronary Dysfunction",[260,318,319,320,321,322,157],"HIIT","high intensity interval exercise training","exercise training","dietary rehabilitation","lifestyle advice","2025-06-17",{"date":325,"type":42},"2025-06-18",{"date":327,"type":42},"2024-11-12",{"date":329,"type":21},"2027-01-01",{"name":331,"class":49},"Royal United Hospitals Bath NHS Foundation Trust",2,{"id":334,"slug":335,"hasResults":11,"nctId":336,"briefTitle":337,"officialTitle":338,"acronym":339,"eligibilityCriteria":340,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":341,"targetDuration":4,"studyType":183,"phases":4,"briefSummary":343,"conditions":344,"keywords":347,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":353,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":359,"locationsCount":4},"100588722","a-multi-center-real-world-clinical-trial-of-caimr-on-two-specific-kinds-of-patients-100588722","NCT06945094","A Multi-center, Real-World Clinical Trial of caIMR on Two Specific Kinds of Patients.","A Multi-center, Real-World Clinical Trial on Assessment of Microcirculatory Status Using Online Coronary Angiography-Derived Index of Microcirculatory Resistance (caIMR) (Flash V)","FlashV","Inclusion Criteria:\n\n1. Age between 18 and 80 years, regardless of gender;\n2. Diagnosed with stable angina, unstable angina, or suspected myocardial ischemia;\n3. targeted vessel stenosis \\\u003C 50% and caIMR values between 20 and 30; or\n\n(3) Targeted vessel stenosis \\\u003C 50%, but with lesion length \\> 20 mm and caFFR \\> 0.8, representing diffuse disease.\n\nExclusion Criteria:\n\n1. Previously undergone percutaneous coronary intervention (PCI);\n2. History of heart failure or myocardial infarction;\n3. Acute myocardial infarction;\n4. Primary or secondary cardiomyopathy;\n5. Primary or secondary severe valvular heart disease;\n6. Severe systemic infections;\n7. Malignant cachectic diseases and an estimated survival of less than one year;\n8. Patients who are currently participating in other clinical trials involving drugs or devices and have not yet reached the primary endpoint of those trials;\n9. Patients whom the investigator deems to have other conditions that make them unsuitable for participation in the clinical trial.",{"count":342,"type":21},508,"The coronary angiography-derived index of microcirculatory resistance (caIMR) can be used to provide a binary assessment whether patients（with stable angina, unstable angina, suspected myocardial ischemia, or coronary artery stenosis of less than 50%, and without cardiomyopathy or obstructive epicardial coronary artery disease） have microcirculatory dysfunction, using a cutoff value of 25.\n\nThis study aims to evaluate the binary classification performance of caIMR in two specific groups of patients: (1) those with caIMR values between 20 and 30, and (2) those with diffuse disease. We will do this by looking at differences in their Seattle Angina Questionnaire (SAQ) scores and their health outcomes over a three-year period.",[31,99,345,346],"Unstable Angina Pectoris","Myocardial Ischemia, Angina Pectoris",[348,349,350,260,351],"Hemodynamics","Computational fluid dynamics","Angiography-derived IMR","stable and unstable angina","2025-04-24",{"date":354,"type":42},"2025-04-27",{"date":356,"type":21},"2025-07-01",{"date":358,"type":21},"2029-12-30",{"name":360,"class":49},"Ge Junbo",{"id":362,"slug":363,"hasResults":11,"nctId":364,"briefTitle":365,"officialTitle":365,"acronym":366,"eligibilityCriteria":367,"healthyVolunteers":11,"sex":58,"minAge":17,"maxAge":4,"enrollmentInfo":368,"targetDuration":4,"studyType":22,"phases":370,"briefSummary":371,"conditions":372,"keywords":373,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":374,"lastUpdatePostDateStruct":375,"startDateStruct":377,"completionDateStruct":379,"leadSponsor":381,"locationsCount":83},"100588960","inorganic-nitrate-as-a-treatment-for-anoca-no-anoca-100588960","NCT06948201","Inorganic Nitrate as a Treatment for ANOCA: NO-ANOCA","NO-ANOCA","Inclusion Criteria:\n\n* Age ≥18 years.\n* Female sex.\n* Willing and able to provide written informed consent.\n* Signs and symptoms of suspected ischemia prompted referral for further evaluation by cardiac catheterization or CCTA within two years of consent.\n* No evidence of obstructive epicardial CAD (stenosis \\>50%) of a major epicardial vessel or an FFR ≤0.80 by invasive catheterization or CCTA. Patients who have not undergone cardiac catheterization of CT angiogram within the last 2 years for chest pain can be scheduled for a screening CT angiogram of the coronary arteries to confirm eligibility.\n* Impaired coronary flow reserve (cut-off values depending on methodology use between ≤2.0 and ≤2.5 by stress testing PET\u002FCMR or Invasive assessment) or Abnormal index of coronary microcirculatory resistance (e.g., IMR \\> 25)\n* SGLT2i Naïve\n\nExclusion Criteria:\n\n* History of non-ischemic cardiomyopathy LVEF \\\u003C40% or hypertrophic cardiomyopathy.\n* History of congestive heart failure, severe pulmonary disease, liver disease\n* History of acute coronary syndrome (ACS) within previous 30 days\n* Stroke within the last 180 days or intracranial hemorrhage at any time.\n* Severe valvular disease\n* Life expectancy \\\u003C3 years, due to non-cardiovascular comorbidity.\n* Pregnancy or women who are breast-feeding\n* Type 1 diabetes mellitus\n* Symptomatic hypotension or systolic BP\\\u003C95 mmHg on 2 consecutive measurements\n* Active malignancy requiring treatment at the time of visit\n* Severe (eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m2 by CKD-EPI), unstable, or rapidly progressing renal disease at the time of randomization\n* History of recurrent UTI\u002Fbladder\u002Fkidney infections\n* Asthma with ongoing wheezing\n* Known or suspected bronchoconstrictive or bronchospastic lung disease (ARDS, emphysema)\n* Greater than first degree heart block\n* Implanted cardiac device\n* Profound sinus bradycardia (heart rates\\\u003C40 beats per minute)\n* Atrial fibrillation or supraventricular arrhythmias at time of imaging\n* Known intolerance of nitrates (other than hypotension)\n* History of reaction to iodinated contrast agents\n* Any orthopedic, neurological, or other condition that prevents participant from exercising\n* Individuals currently taking nitroglycerine (or inorganic nitrates), PDE-5 inhibitors (ex: Cialis, Viagra), and xanthine oxidase inhibitors (ex: Allopurinol)\n* Smokers within the last 5 years\n* Prisoners\n* Cognitively impaired individuals\n* Non-English Speaking",{"count":369,"type":21},8,[64],"The purpose of this study is to see if inorganic nitrate in the form of beetroot juice helps blood flow and physical fitness in women with ANOCA and CMD. The main questions it aims to answer are:\n\nAIM 1: Test the hypothesis that fourteen days of nitrate rich beetroot juice will increase cardiac perfusion and improve quality of life compared to placebo.\n\nAIM 2: Test the hypothesis that fourteen days of nitrate rich beetroot juice will increase physical fitness and reduce angina and dyspnea symptoms compared to placebo.\n\nExploratory AIM 3: Test the hypothesis that fourteen days of nitrate rich beetroot juice will improve vascular health and function.\n\nParticipants will:\n\n* Take study beverage for 4 weeks total.\n* Stress Cardiac magnetic resonance imaging and 12 lead electrocardiograms\n* Complete questionnaires\n* Cycling exercise test\n* Non invasive vascular testing\n* Blood draws",[31,288],[156,71,292,30,293,294],"2025-04-23",{"date":376,"type":42},"2025-04-29",{"date":378,"type":21},"2025-05",{"date":380,"type":21},"2026-06",{"name":303,"class":49},{"id":383,"slug":384,"hasResults":11,"nctId":385,"briefTitle":386,"officialTitle":387,"acronym":388,"eligibilityCriteria":389,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":390,"targetDuration":392,"studyType":183,"phases":4,"briefSummary":393,"conditions":394,"keywords":397,"overallStatus":164,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":402,"completionDateStruct":404,"leadSponsor":406,"locationsCount":83},"100561290","inoca-na-a-local-prospective-registry-100561290","NCT06588244","INOCA-NA a Local Prospective Registry","Ischemia in Patients with Non- Obstructive Disease (INOCA) - a Local Prospective Registry (INOCA-Naples)","INOCA-NA","Inclusion Criteria:\n\n* Clinical presentation of chronic ischemic heart dis- ease (IHD), requiring coronary angiography for the diagnosis;\n* Absence of obstructive coronary artery disease (CAD) at coronary angiography;\n* Age \\> 18 years.\n* Ability to provide a valid informed consent to the study procedure at the time of baseline evaluation;\n\nExclusion Criteria:\n\nClinical presentation of acute coronary syndrome (ACS) or cardiogenic shock;\n\n* Presence of obstructive CAD with at least 1 significant coronary artery stenosis, defined as diameterstenosis \\>50% and FFR ≤0.80 (or iFR\u002FRFR ≤0.89);\n* Previous coronary artery bypass grafting (CABG);\n* Left ventricular systolic dysfunction, defined as ejection fraction (EF) \\<40%;\n* Severe valvular heart disease;\n* Pregnant or breastfeeding women\n* Known hypersensitivity or contraindication to any of the drugs used for coronary physiology testing (adenosine, nitrates, acetylcholine)\n* Inability or unwillingness to provide a valid in- formed consent to the study procedure at the time of baseline evaluation.",{"count":391,"type":21},250,"1 Year","The present study has the following objectives:\n\n1. To investigate the prevalence of INOCA in patients referring for a clinically indicated coronary angiography (CA) c\u002Fo Division of Cardiology - Federico II University Hospital;\n2. To stratify in INOCA endotypes patients according to the presence or absence of alternative (i.e. non obstructive CAD) causes of myocardial ischemia detected during CA clinically indicated through physiology tests;\n3. to implement a stratified therapy in these patients considering the different INOCA endotypes and evaluate the impact on angina class and quality of life as well as cardiac hospitalization and coronary revascularization during 5 year follow up",[395,151,396,31],"Ischemia, Myocardial","Microcirculatory Status",[72,30,398],"VSA","2025-03-12",{"date":401,"type":42},"2025-03-17",{"date":403,"type":42},"2024-09-19",{"date":405,"type":21},"2027-09-01",{"name":407,"class":49},"Federico II University",{"id":409,"slug":410,"hasResults":11,"nctId":411,"briefTitle":412,"officialTitle":413,"acronym":414,"eligibilityCriteria":415,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":416,"targetDuration":4,"studyType":22,"phases":417,"briefSummary":418,"conditions":419,"keywords":420,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":423,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":429,"locationsCount":4},"100574170","phase-3-nebivolol-anoca-treatment-randomized-trial-100574170","NCT06755801","Nebivolol ANOCA Treatment Randomized Trial","Microvascular Obstruction Treatment and Outcomes Randomized Study.","MOTORS","Inclusion Criteria:\n\n* Age 18 years or older.\n\n  * Presence of stable angina symptoms, defined as compatible symptoms occurring at least once weekly in the last three months.\n  * Absence of functionally significant epicardial coronary artery disease (FFR \\> 0.80).\n  * Microvascular functional study showing CFR\\\u003C 2,0 and\u002For IMR ≥ 25.\n\nExclusion Criteria:\n\n* Allergy or contraindication to the use of beta-blockers.\n* Indication for beta-blocker treatment due to another pathology.\n* Ventricular dysfunction (LVEF \\\u003C 45%).\n* Percutaneous coronary revascularization in the last 6 months.\n* History of surgical revascularization.\n* First-degree atrioventricular block or bifascicular block.\n* Presence of hemodynamically significant valvulopathy.\n* Presence of cardiomyopathy or congenital cardiac anomaly.\n* Severe renal insufficiency (eGFR \\\u003C 30 ml\u002Fmin).\n* Liver failure (history of cirrhosis or transaminase elevation \\> 3 times the upper limit of normal).\n* Pregnant or lactating women.",{"count":283,"type":21},[122],"To determine the effectiveness of the beta-blocker nebivolol in controlling symptoms and improving the quality of life in patients with angina and coronary microvascular dysfunction.",[67,31],[289,421,291],"Betablockers","2024-12-31",{"date":424,"type":42},"2025-01-01",{"date":426,"type":21},"2025-04-01",{"date":428,"type":21},"2026-09-30",{"name":430,"class":49},"Spanish Society of Cardiology"]